2024MAY02: Our hosting provider has resolved some DB connectivity issues. We may experience some more outages as the issue is resolved. We apologize for the inconvenience. Dismiss and don't show again
  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

dkNET community events and announcements in February, 2023

Dear dkNET Community,

dkNET provides updates on activities of interest to the NIDDK-supported community. You could keep up to date on these activities through our Twitter feed @dkNET_info, through our Community Calendar, or through dkNET e-mail list. If you have an event or funding opportunities you'd like to advertise, please contact us info_at_dknet.org.


Events in February 2023


Feb. 01-02, 2023

2023 NIH Grants Virtual Conference

Learn about NIH grants policies!
Interact with NIH experts!
Engage and network with your peers!
Gather resources to use and share with colleagues!

More information: https://grants.nih.gov/learning-center/conference


Feb. 05-10, 2023

Mitochondria Biology Meeting

The Mitochondria in Health and Disease GRC is a premier, international scientific conference focused on advancing the frontiers of science through the presentation of cutting-edge and unpublished research, prioritizing time for discussion after each talk and fostering informal interactions among scientists of all career stages. The conference program includes a diverse range of speakers and discussion leaders from institutions and organizations worldwide, concentrating on the latest developments in the field. The conference is five days long and held in a remote location to increase the sense of camaraderie and create scientific communities, with lasting collaborations and friendships. In addition to premier talks, the conference has designated time for poster sessions from individuals of all career stages, and afternoon free time and communal meals allow for informal networking opportunities with leaders in the field. 

Location:  Barga, 55051 Barga, Province of Lucca, Italy

More information: https://www.grc.org/mitochondria-in-health-and-disease-conference/2023/


Feb. 07, 2023

e-IDG Symposium Series: Understudied Protein Initiative

Speakers: Dr. Georg Kustatscher, PhD (The University of Edinburgh) and Dr. Juri Rappsilber, PhD (Technical University of Berlin and Wellcome Centre Cell Biology, Edinburgh)

More information: https://www.eventbrite.com/e/idg-symposium-series-feb-7-2023-registration-526808497397

Feb. 08, 2023

Diabetes Research Virtual Seminar Series: The Redox Network: Master Regulator of Metabolism

Speaker: Barbara E. Corkey, PhD. Professor Emeritus of Medicine and BiochemistryBoston University School of Medicine.

More information: https://diabetes-virtual-seminar.org/


Feb. 10, 2023

dkNET Webinar: Sample Size Shop

Presenters: Kylie K. Harrall, MS, Research Instructor, Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, University of Colorado Anschutz Medical Campus

Abstract

Planning a reproducible study requires selecting a sample size which will ensure appropriate statistical power. Free point-and-click software (Kreidler et al., Journal of Statistical Software, 2013, 10.18637/jss.v054.i10) makes it easy to select a sample size for clustered and longitudinal designs with linear mixed models. The software, a suite of training modules, and reference materials are freely available online (www.SampleSizeShop.org ). The software interface and training materials are aimed at biomedical scientists, included those funded by NIDDK. We give examples of study designs for which the software will compute power and sample size, including a study with clustering, a study with longitudinal repeated measures, and a study with multiple outcomes, where heterogeneity of response among subgroups is of interest.


The top 3 key questions that the Sample Size Shop can answer:

1. What free, online, point-and-click, wizard-style, NIH-funded, validated, published power and sample size software provides calculations for studies with clusters, longitudinal studies, and longitudinal studies with clusters?

2. Can GLIMMPSE (www.SampleSizeShop.org) compute power and sample size for randomized controlled clinical trials and observational studies funded by NIDDK?

3. Why use validated power and sample size software instead of writing simulations?

More information: https://dknet.org/about/blog/2577


Feb. 12, 2023

Gordon Research Conference Application Deadline: Examining the Intersection Between Systemic and Cellular Metabolism and Lifestyle Factors to Understand Health and Disease

The Metabolomics and Human Health GRC is a premier, international scientific conference focused on advancing the frontiers of science through the presentation of cutting-edge and unpublished research, prioritizing time for discussion after each talk and fostering informal interactions among scientists of all career stages. The conference program includes a diverse range of speakers and discussion leaders from institutions and organizations worldwide, concentrating on the latest developments in the field. The conference is five days long and held in a remote location to increase the sense of camaraderie and create scientific communities, with lasting collaborations and friendships. In addition to premier talks, the conference has designated time for poster sessions from individuals of all career stages, and afternoon free time and communal meals allow for informal networking opportunities with leaders in the field. Metabolomics is the comprehensive study of the metabolome, the repertoire of metabolites present in cells, tissues, and body fluids. More recently, these metabolites are being implicated in the promotion of human health. The human metabolic profile is influenced by a number of factors including diet, genetics, environmental factors and the microbiome. Understanding the influence of these factors at a cellular and systemic level is key to deciphering the role of metabolites in human health and promotion of lifespan.In this Gordon Conference series, we highlight state of the art metabolomics technologies and how such technologies can be used to study Human health. The conference will cover exciting new applications in the field such as Precision Nutrition, Human Ageing, response to Therapies (Precision Medicine), Exposome and Human Health. Application deadline: Feb. 12, 2023. Conference dates: March 12-17, 2023.

Location:  Lucca, 55100 Lucca, Province of Lucca, Italy

More information: https://www.grc.org/metabolomics-and-human-health-conference/2023/


Feb. 13, 2023

Keystone Symposia Scholarship and Abstract Deadline: Type 2 Diabetes: Understanding its Early Drivers and the Road to Therapeutics

Early detection and consequential intervention are key to good treatment outcomes and avoidance of complications for most diseases. Arguably, this may not be the case for Type-2 diabetes (T2D) where measures of elevated glucose and HbA1C, historically related to a predicted onset of retinopathy, occur too late in the pathogenesis of the disease. We require improved markers of T2D are necessary to better diagnose and treat this prevalent disease at early stages. With the advent of precision medicine, now is the time to re-examine the pathogenesis of type 2 diabetes at the molecular level. Which subsets of T2D define the rate of progression to certain diabetes complications? Can early molecular drivers of the disease be better identified? What factors contribute to dysfunctional inter-organ communication and altered metabolic homeostasis? Does pancreatic ß-cell failure really define the disease? If detected early enough, can we envision ways to reverse, or even prevention, of T2D be practically envisioned? With several commonly used T2D therapies soon coming off of patent this may be conceivable. Nonetheless, there remains a need for more effective therapeutic approaches, not just for T2D, but also for its comorbidities. This Keystone Symposium will examine the current knowledge of T2D pathogenesis and the therapeutic landscape - with a view towards earlier diagnosis, more effective and tailored T2D treatment regime(s) that also prevent or significantly delay the journey to complications and comorbidities. Conference dates: May 1-4, 2023. Abstract and scholarship deadline: February 13, 2023.

Location:  Palm Springs, CA, USA

More information: https://www.keystonesymposia.org/conferences/conference-listing/meeting?eventid=6803

Feb. 15, 2023

58th EASD Minkowski Prize awardee nomination deadline

The Minkowski Prize will be given in relation to research which has been carried out by an outstanding researcher normally residing in Europe. It is awarded for distinction manifested by publications which contribute to the advancement of knowledge concerning diabetes.

  • Candidates must be an EASD Member and
  • Candidates should be resident in Europe and
  • Candidates should be younger than 45yrs in the year of nomination and/or
  • their MD or PhD degree should have been obtained within the last 15 years
  • Board Members of EASD are not eligible for nomination

More information: https://www.easd.org/prizes/minkowski.html


Feb. 15, 2023

19th IDS Congress Paris 2023 abstract deadline

The Immunology of Diabetes Society (IDS) is a scientific society dedicated to improving understanding and treatment of type 1 diabetes. IDS organizes a Congress every 18 months in major centres in Europe, North America and Asia/Oceania at which there are scientific presentations to further this goal. Conference dates: May 23-27, 2023. Abstract submission deadline: Feb. 15, 2023.

Location:  Paris, France

More information: https://www.idsparis2023.com/


Feb. 24, 2023

dkNET New Investigator Pilot Program in Bioinformatics Webinar Series

Abstract

Women with gestational diabetes mellitus (GDM) are at high risk of developing glucose intolerance after delivery. In the long term, women with GDM have a nearly 10-fold higher risk of developing type 2 diabetes mellitus (T2D) than women without GDM. The American Diabetes Association (ADA) and the American College of Obstetrics and Gynecology (ACOG) recommend that women with GDM undergo a 75-g oral glucose tolerance test (OGTT) between four and 12 weeks postpartum, and periodically thereafter. However, postpartum glucose screening (PGS) rate is historically low despite of various interventions to improve such rate. We hypothesized that PGS rate is lower among postpartum homeless women than their housed counterparts, and that interventions to improve PGS rate among postpartum homeless women with GDM should be tailored to their unique circumstances. The Japanese Society of Diabetes and Pregnancy (JSDP) modified the method to perform PGS with random plasma glucose (RPG) and glycated hemoglobin (HbA1c), which are simple and less invasive, to reduce the risk of COVID-19 infection by shortening the time spent in the hospital. RPG or HbA1c test do not require fasting. Therefore, homeless women who utilized care for other reasons could have the test as PGS. Given the barriers faced by homeless individuals, we hypothesize that RPG and HbA1c at healthcare utilizations during the postpartum period could be one of the strategies to identify high-risk individuals early because 1] healthcare utilizations are an opportunity for healthcare providers and social workers to educate homeless patients on GDM and their insurance eligibility and coverage for the screening, and 2] the physical barriers to health care access, which are often cited as a reason for the low PGS rate, are removed.

   This proposed study will use administrative data from five states (AZ, CO, NC, NJ, and OR), which collectively include 9.3% of the US female homeless population. Each state will provide detailed, linked, multi-level, anonymized data for postpartum homeless women from four sources: 1] Medicaid claims; 2] Homeless Management Information System (HMIS); 3] birth records; and 4] the American Hospital Association (AHA) database to obtain hospital characteristics. With data from 2013 to 2020, an estimated sample size of 24,000 homeless women who delivered babies and 3,290 postpartum homeless women with GDM will be included.

   First, we will estimate rates of GDM and PGS among homeless women. Second, we will estimate the cost-effectiveness of performing RPG and HbA1c tests when they utilized care among homeless women with GDM who missed the PGS 12 weeks postpartum. For individuals who meet the criteria for glucose intolerance defined by JSDP, OGTT will be performed to confirm the results in order to begin intervention. The effect of lifetime horizon will be estimated using the quality-adjusted life-years (QALYs).

   This project has the potential to change clinical practice by providing evidence that performing RPG and HbA1c at the healthcare utilization during the postpartum period will be a cost-effective strategy to improve health status among homeless with GDM.


Presenter: Rie Sakai-Bizmark, PhD. Assistant Professor, The Lundquist Institute at Harbor-UCLA Medical Center, David Geffen School of Medicine at UCLA

More information: https://dknet.org/about/webinar


Feb. 24, 2023

PKD Connect 2023 Abstract Submission Deadline

The PKD Foundation is looking forward to the 2023 PKD Connect Conference to be held in Denver June 23-24, 2023. PKD Connect is an annual, national conference bringing all members of the PKD community together. We will have a PKD Research Symposium on Saturday, June 24 and invite our researcher community to attend to meet patients and their families and talk about their latest research. To prepare, the Foundation is requesting submissions of research abstracts to be considered for both the oral breakout presentations and the poster session in the following categories:
Potential session themes and topics of interest include:
·        Dietary Interventions and Metabolism
·        Genetic Medicines in Cystic Diseases
·        Role of the Cyst Microenvironment in ADPKD
·        ARPKD and Cystic Diseases in Children

Research topics do not need to belong to these categories in order to be considered; we encourage you to submit any relevant research as long as you can speak to the translational capacity to a partially patient-facing audience.
Abstract deadline: February 24, 2023. 

Location:  Denver, CO, USA

More information: https://forms.office.com/pages/responsepage.aspx?id=D0RS8RRncke_iC7e42ehfR8QrClNaSdAuYjLZkUxpiZUNDRQSjRXVjBQU1Q3UTZHN1JTOTRCS1lPUC4u


Funding Opportunities Information and Deadlines in February 2023

Feb. 03, 2023

NIDDK Funding Opportunity Application Due: Notice of Special Interest: Administrative Supplements to Support Emerging Physician-Scientists to Develop Research Expertise in Diabetes, Endocrinology and Metabolic Diseases

The purpose of the NIDDK’s Division of Diabetes, Endocrinology and Metabolic Diseases (DDEMD) Administrative Supplement Program is to enable additional clinical perspectives to be brought to on-going research projects within the Division's mission and to enhance the research expertise of selected physicians.The program will provide supplementary funds to support advanced research opportunities for exceptional emerging physician-scientists (hereafter, "candidates") holding the MD or equivalent or MD/PhD degrees, and who are early in their research careers. The supplement is intended to allow candidates to expand their research experience to help them transition beyond their clinical training to the next stage of their research careers as physician-scientists.

More Information: https://dknet.org/about/dknetnews/2506

Feb. 03, 2023

NIH Funding Opportunity Application Due: Pilot Projects Enhancing Utility and Usage of Common Fund Data Sets

The Common Fund Data Ecosystem (CFDE) program has announced a new funding opportunity (RFA-RM-23-003) seeking applications for pilot studies that use Common Fund program data sets to generate new, cross-cutting biological hypotheses and improve the utility of Common Fund data. Application Due Date: February 3, 2023.

More information: https://dknet.org/about/dknetnews/2537


Feb. 05, 2023

NIH Funding Opportunity Application Due: Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)

The purpose of this Funding Opportunity Announcement (FOA) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, scale-up, and sustainability of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies. Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (“de-implement”) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services (e.g. cancer screening) that may have dropped off amidst the ongoing COVID pandemic are encouraged.
Letter of Intent Deadline: 30 days prior to the application due date
Application Deadline: June 15, 2022; October 5, 2022; February 05, 2023 (...)
More Informationhttps://grants.nih.gov/grants/guide/pa-files/par-22-105.html

Feb. 08, 2023

NIDDK Funding Opportunity Letter of Intent Due: Fostering Research With Additional Resources and Development (FORWARD) Urology Centers

The overall goal of the Fostering Research with Additional Resources and Development (FORWARD) Urology Centers program is to foster and expand the urology (excluding cancer) research community. The objective of each FORWARD Urology Center will be to support a Research Project designed and conducted by a collaborative, multidisciplinary team comprising primarily of junior investigators with at least one Early Stage Investigator (ESI) and/or researcher new to urology. Research Project data are expected to support one or more follow-on independent grant applications (e.g., R01s) submitted by Research Project Team investigators. The Center PD(s)/PI(s) will lead an Administrative (Project Support) Core to provide guidance to the Research Project Team to help ensure the research aims are met and to aid them in their successful integration into the broader urologic research field. The Center will leverage intra- and extra-institutional resources, collaborations and facilities and engage as a member of NIDDK’s CAIRIBU (Collaborating for the Advancement of Interdisciplinary Research in Benign Urology) Program. Letter of Intent Due Date: February 8, 2023; Application Due Date: March 8, 2023.

More information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-027.html




Feb. 15, 2023

NIDDK Funding Opportunity: Notice of Special Interest to Encourage Eligible NIH HEAL Initiative Awardees to Apply for PA-20-222: Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed) Application Due Date

Description: The NIH has a strong interest in the diversity of the NIH-funded research enterprise (see NIH notice NOT-OD-20-031) and encourages institutions to diversify their scientific workforce by increasing the participation of individuals from groups identified as underrepresented in the biomedical, clinical, behavioral, and social sciences. Participating institutes continue to support these efforts through ongoing programs and supplement funding opportunities. This specific notice reiterates this interest and encourages eligible grant and cooperative agreement awardees in the HEAL Initiative community to apply for administrative supplements in response to PA-20-222 (or any subsequent reissuances), Research Supplements to Promote Diversity in Health-Related Research (Admin Supp - Clinical Trial Not Allowed). This notice is part of the NIH’s Helping to End Addiction Long-term (HEAL) Initiative to speed scientific solutions to the national opioid public health crisis. The NIH HEAL Initiative is a trans-NIH effort to (1) improve prevention and treatment strategies for opioid misuse and addiction and (2) enhance pain management. More information about the HEAL Initiative is available at: https://heal.nih.gov/.

More Information: https://grants.nih.gov/grants/guide/notice-files/not-ns-20-107.html



Feb. 17, 2023

Funding Opportunity Application Due: Diabetes-Docs: Physician-Scientist Career Development Program (DiabDocs)

The DiabDocs program is now soliciting a second cycle of letters of intent for applications for a mentored career development program from a diverse group of early career physician scientists engaged in research relevant to type 1 diabetes (T1D) including basic, translational, clinical, epidemiology/biostatistical, informatics, health services or health policy projects. Awards will provide promising investigators the opportunity to be mentored in research-intensive settings at their home institutions to create the research foundation to compete successfully for NIH K08/23 or similar Career Development Awards. Successful applicants will be early career faculty with experience and training in relevant areas who have demonstrated skills and potential in research and articulate a strong commitment to an academic research career. Application Due Date: February 17, 2023. More Information: https://dknet.org/about/dknetnews/2505

Feb. 20, 2023

NIDDK Funding Opportunity Letter of Intent Due: New Investigator Gateway Awards for Collaborative T1D Research (R03 Clinical Trial Not Allowed)

The New Investigator Gateway Award in T1D Research is designed to support a robust pipeline of innovative projects and talented new investigators in T1D research. In addition to providing support for preliminary research, the Gateway program provides an opportunity for new Program Directors/Principal Investigators (PD/PIs) to pursue their studies within the intellectual environment of a select number of large, ongoing collaborative research programs. Embedding awardees within an established scientific framework in each of these consortia will provide unique opportunities for New and Early Stage Investigators to increase their understanding of key questions in the field, to network, and to establish unique and potentially long-lasting collaborations that will propel their careers forward. Bringing New and Early Stage Investigators into existing collaborative research networks will also benefit the networks by providing new ideas and perspectives.
Letter of Intent Deadline(s): May 1, 2022 and February 20, 2023
Application Deadline (New Application): June 1, 2022 and March 20, 2023
More Information: https://dknet.org/about/dknetnews/2379

Feb. 21, 2023

NIDDK Funding Opportunity Application Due: Integrated Physiology of Exocrine and Endocrine Pancreas in Type 1 Diabetes (R01 - Clinical Trial Not Allowed)

This Funding Opportunity will support multi-disciplinary teams to examine interactions between exocrine and endocrine pancreas to support the study of T1D. The purpose of this opportunity is to encourage integrated study of the whole pancreas to enable characterization of direct and indirect crosstalk between exocrine and endocrine compartments, and identification of the mechanisms by which that crosstalk occurs and can be disrupted in T1D and other forms of diabetes. Development of assays or platforms to allow for broader investigation into these questions could also be supported.
Letter of Intent Deadline: January 21, 2023
Application Deadline: February 21, 2023
More Information: https://dknet.org/about/dknetnews/2479

Feb. 28, 2023

NIDDK Funding Opportunity Application Due: Collaborative Research Using Biosamples from Type 1 Diabetes Clinical Studies (R01 - Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites applications for studies of type 1 diabetes etiology and pathogenesis using data and samples from clinical trials and studies. This opportunity is intended to fund investigative teams collaborating to answer important questions about disease mechanisms leading to improved prevention of type 1 diabetes.
Letter of Intent Deadline: January 28, 2022 ; September 26, 2023
Application Deadline: February 28, 2023 ; October 26, 2023
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-021.html

Feb. 28, 2023

NIDDK Funding Opportunity Application Due: Clinical, Behavioral, and Physiological Studies of Open- and Closed-loop Platforms: Toward Personalized, Fully Automated, Accessible Systems (R01 Clinical Trial Required)

The purpose of this funding opportunity announcement (FOA) is to promote clinical research using current and emerging technologies to address barriers that limit progress toward physiological pancreatic hormone replacement open- and closed-loop systems. It will support research to: 1) test and improve the safety, reliability, and clinical efficacy of these technologies; 2) address behavioral/psychosocial factors that play a role in the usability and acceptance of these systems and validation of measures that may be used as outcomes for the demonstration of efficacy and benefit; 3) test these technologies in subpopulations of patients not usually included in clinical trials who may benefit the most from their use; 4) test these technologies in individuals who are underserved or in low income and/or racial and ethnic minority groups, and better understand disparities in the use and adoption of these systems; and 5) use the technologies as tools to advance understanding of glucose regulation and its pathophysiology in patients with type 1 diabetes (T1D) including counter-regulation and impaired awareness of hypoglycemia. Research goals include improved metabolic control with decreased glycemic excursions, prevention of acute and chronic complications, and improved quality of life in patients with diabetes and their caregivers. Only human studies will be considered responsive to this FOA, applications involving animal or in vitro studies are not responsive to this FOA.
Letter of Intent Deadline(s): January 28, 2023; September 26, 2023
Application Deadline(s): February 28, 2023; October 26, 2023
More Information: https://grants.nih.gov/grants/guide/rfa-files/rfa-dk-22-020.html

Feb. 28, 2023

NIDDK Funding Opportunity Letter of Intent Due: Human Islet Research Network (HIRN) Pancreas Knowledgebase Program (PanKbase) (U24 - Clinical Trial Not Allowed)

This Funding Opportunity Announcement (FOA) invites applications to develop a centralized resource of the human pancreas for diabetes research that will provide access to deeply curated high-quality datasets, knowledge in computable forms, and advanced data science tools and workflows; and enable open and reproducible multidisciplinary collaboration toward accelerating biomarker and therapeutic target development. The program will become a component of the Human Islet Research Network or HIRN (https://hirnetwork.org/).Letter of Intent Due Date: February 28, 2023. Application Due Date: March 31, 2023.
More Information: https://dknet.org/about/dknetnews/2497

Feb. 28, 2023

NIDDK Funding Opportunity Application Due: NIDDK Investigator Award to Support Mentoring of Early Career Researchers from Diverse Backgrounds

The purpose of the NIDDK Investigator Award to Support Mentoring of Early Career Researchers from Diverse Backgrounds is to provide protected effort and resources to established, NIDDK-funded, mentors to provide high quality mentoring to graduate students and postdoctoral fellows from diverse backgrounds, including those from underrepresented groups (see, e.g., Notice of NIH’s Interest in Diversity). Program Directors/Principals Investigators (PD/PIs) (mentors) must be conducting research that falls within the missions of the NIDDK and such research programs should serve as the framework around which mentoring activities are constructed. PD/PIs/applicants must have a demonstrable track record of mentoring early career researchers from diverse backgrounds, including those from underrepresented groups. This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Letter of Intent Due Date: January 28, 2023; Application Due Date: February 28, 2023.

More information: https://dknet.org/about/dknetnews/2538


Feb. 28, 2023

NIDDK Funding Opportunity Letter of Intent Due: NIDDK Information Network Coordinating Unit: dkNET-CU

The purpose of this FOA is to continue the development and expansion of the NIDDK Information Network (dkNET) under the direction of the dkNET Coordinating Unit (dkNET-CU). dkNET supports the NIDDK community’s needs in data science by providing an information portal that connects users to data, analytical tools, and other biomedical research resources. Additionally, dkNET supports researchers by providing a hub for data-driven hypothesis generation; a suite of tools that assist users in FAIR (Findable, Accessible, Interoperable, Reusable) practice, and in improving rigor and reproducibility in research; and a variety of programs to enhance community engagement and workforce development. The dkNET-CU will be responsible for providing the scientific direction, vision, and administrative management to advance dkNET goals. Letter of Intent Due Date: February 28, 2023; Application Due Date: March 31, 2023.

More information: https://dknet.org/about/dknetnews/2527


X

Are you sure you want to delete that component?